Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Results of a phase II study evaluating trifluridine/tipiracil plus nivolumab in patients with heavily pretreated microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).
Authors
Manish R. Patel
Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL
Manish R. Patel, Gerald Steven Falchook, Kensuke Hamada, Lukas Makris, Robert E. Winkler, Gilad Shalag Gordon, Johanna C. Bendell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02860546
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 48)
DOI
10.1200/JCO.2019.37.8_suppl.48
Abstract #
48
Poster Bd #
C2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
The esophageal cancer cohort of a phase 2 trial of E7389-LF (liposomal formulation of eribulin) + nivolumab.
First Author: Akira Ooki
Poster
2017 Gastrointestinal Cancers Symposium
Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC).
First Author: Howard S. Hochster
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Safety and efficacy of ONO-4578 plus nivolumab in metastatic colorectal cancer.
First Author: Akihito Kawazoe
Poster
2023 ASCO Annual Meeting
A multicenter randomized phase II trial comparing CAPOXIRI + bevacizumab with FOLFOXIRI + bevacizumab as first-line treatment in patients with metastatic colorectal cancer: Primary results of the QUATTRO-II study.
First Author: Hideaki Bando